Financhill
Buy
52

PDEX Quote, Financials, Valuation and Earnings

Last price:
$42.58
Seasonality move :
4.06%
Day range:
$40.00 - $41.74
52-week range:
$16.84 - $70.26
Dividend yield:
0%
P/E ratio:
14.54x
P/S ratio:
2.13x
P/B ratio:
3.75x
Volume:
17.2K
Avg. volume:
47K
1-year change:
109.99%
Market cap:
$132.3M
Revenue:
$53.8M
EPS (TTM):
$2.79

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PDEX
Pro-Dex
$17.7M $0.47 19.14% 4.44% $56.00
ABT
Abbott Laboratories
$10.4B $1.07 6.13% 68.77% $140.89
BSX
Boston Scientific
$4.6B $0.67 18.78% 229.3% $117.05
OM
Outset Medical
$27.8M -$0.95 7.36% -90.13% $26.50
PODD
Insulet
$543.3M $0.79 25.31% -64.13% $336.00
SYK
Stryker
$5.7B $2.73 9.23% 43.28% $421.46
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PDEX
Pro-Dex
$40.57 $56.00 $132.3M 14.54x $0.00 0% 2.13x
ABT
Abbott Laboratories
$134.01 $140.89 $233.2B 17.38x $0.59 1.7% 5.53x
BSX
Boston Scientific
$101.49 $117.05 $150.1B 74.08x $0.00 0% 8.61x
OM
Outset Medical
$20.46 $26.50 $362.6M -- $0.00 0% 0.77x
PODD
Insulet
$306.59 $336.00 $21.6B 55.14x $0.00 0% 10.32x
SYK
Stryker
$377.12 $421.46 $144.1B 50.96x $0.84 0.87% 6.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PDEX
Pro-Dex
34.14% -1.397 11.31% 1.41x
ABT
Abbott Laboratories
21.34% 0.731 6.18% 1.27x
BSX
Boston Scientific
33.49% 0.843 7.48% 0.68x
OM
Outset Medical
35.65% 3.445 47.09% 6.60x
PODD
Insulet
56.03% 2.516 9.18% 3.24x
SYK
Stryker
44.5% 1.087 12.02% 0.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PDEX
Pro-Dex
$5.8M $3.6M 20.23% 29.31% 27.56% $574K
ABT
Abbott Laboratories
$5.9B $1.7B 23.5% 31.31% 18.43% $933M
BSX
Boston Scientific
$3.2B $937M 6.35% 9.57% 19.02% $277M
OM
Outset Medical
$11.1M -$16.4M -44.16% -140.06% -74.31% -$25.8M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
SYK
Stryker
$3.7B $872M 8.33% 14.2% 14.87% $127M

Pro-Dex vs. Competitors

  • Which has Higher Returns PDEX or ABT?

    Abbott Laboratories has a net margin of 18.81% compared to Pro-Dex's net margin of 12.79%. Pro-Dex's return on equity of 29.31% beat Abbott Laboratories's return on equity of 31.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    ABT
    Abbott Laboratories
    56.86% $0.76 $62.3B
  • What do Analysts Say About PDEX or ABT?

    Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 38.03%. On the other hand Abbott Laboratories has an analysts' consensus of $140.89 which suggests that it could grow by 5.14%. Given that Pro-Dex has higher upside potential than Abbott Laboratories, analysts believe Pro-Dex is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    ABT
    Abbott Laboratories
    12 10 0
  • Is PDEX or ABT More Risky?

    Pro-Dex has a beta of 0.169, which suggesting that the stock is 83.086% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.647%.

  • Which is a Better Dividend Stock PDEX or ABT?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.7% to investors and pays a quarterly dividend of $0.59 per share. Pro-Dex pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PDEX or ABT?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Pro-Dex's net income of $3.3M is lower than Abbott Laboratories's net income of $1.3B. Notably, Pro-Dex's price-to-earnings ratio is 14.54x while Abbott Laboratories's PE ratio is 17.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.13x versus 5.53x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.13x 14.54x $17.4M $3.3M
    ABT
    Abbott Laboratories
    5.53x 17.38x $10.4B $1.3B
  • Which has Higher Returns PDEX or BSX?

    Boston Scientific has a net margin of 18.81% compared to Pro-Dex's net margin of 14.45%. Pro-Dex's return on equity of 29.31% beat Boston Scientific's return on equity of 9.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    BSX
    Boston Scientific
    68.84% $0.45 $33.6B
  • What do Analysts Say About PDEX or BSX?

    Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 38.03%. On the other hand Boston Scientific has an analysts' consensus of $117.05 which suggests that it could grow by 15.33%. Given that Pro-Dex has higher upside potential than Boston Scientific, analysts believe Pro-Dex is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    BSX
    Boston Scientific
    24 3 0
  • Is PDEX or BSX More Risky?

    Pro-Dex has a beta of 0.169, which suggesting that the stock is 83.086% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

  • Which is a Better Dividend Stock PDEX or BSX?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or BSX?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Pro-Dex's net income of $3.3M is lower than Boston Scientific's net income of $674M. Notably, Pro-Dex's price-to-earnings ratio is 14.54x while Boston Scientific's PE ratio is 74.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.13x versus 8.61x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.13x 14.54x $17.4M $3.3M
    BSX
    Boston Scientific
    8.61x 74.08x $4.7B $674M
  • Which has Higher Returns PDEX or OM?

    Outset Medical has a net margin of 18.81% compared to Pro-Dex's net margin of -86.66%. Pro-Dex's return on equity of 29.31% beat Outset Medical's return on equity of -140.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    OM
    Outset Medical
    37.19% -$3.66 $264M
  • What do Analysts Say About PDEX or OM?

    Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 38.03%. On the other hand Outset Medical has an analysts' consensus of $26.50 which suggests that it could grow by 29.52%. Given that Pro-Dex has higher upside potential than Outset Medical, analysts believe Pro-Dex is more attractive than Outset Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    OM
    Outset Medical
    3 2 0
  • Is PDEX or OM More Risky?

    Pro-Dex has a beta of 0.169, which suggesting that the stock is 83.086% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PDEX or OM?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or OM?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Outset Medical quarterly revenues of $29.8M. Pro-Dex's net income of $3.3M is higher than Outset Medical's net income of -$25.8M. Notably, Pro-Dex's price-to-earnings ratio is 14.54x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.13x versus 0.77x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.13x 14.54x $17.4M $3.3M
    OM
    Outset Medical
    0.77x -- $29.8M -$25.8M
  • Which has Higher Returns PDEX or PODD?

    Insulet has a net margin of 18.81% compared to Pro-Dex's net margin of 6.22%. Pro-Dex's return on equity of 29.31% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About PDEX or PODD?

    Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 38.03%. On the other hand Insulet has an analysts' consensus of $336.00 which suggests that it could grow by 9.59%. Given that Pro-Dex has higher upside potential than Insulet, analysts believe Pro-Dex is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    PODD
    Insulet
    15 2 0
  • Is PDEX or PODD More Risky?

    Pro-Dex has a beta of 0.169, which suggesting that the stock is 83.086% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

  • Which is a Better Dividend Stock PDEX or PODD?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or PODD?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Insulet quarterly revenues of $569M. Pro-Dex's net income of $3.3M is lower than Insulet's net income of $35.4M. Notably, Pro-Dex's price-to-earnings ratio is 14.54x while Insulet's PE ratio is 55.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.13x versus 10.32x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.13x 14.54x $17.4M $3.3M
    PODD
    Insulet
    10.32x 55.14x $569M $35.4M
  • Which has Higher Returns PDEX or SYK?

    Stryker has a net margin of 18.81% compared to Pro-Dex's net margin of 11.15%. Pro-Dex's return on equity of 29.31% beat Stryker's return on equity of 14.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    SYK
    Stryker
    63.83% $1.69 $37.7B
  • What do Analysts Say About PDEX or SYK?

    Pro-Dex has a consensus price target of $56.00, signalling upside risk potential of 38.03%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 11.76%. Given that Pro-Dex has higher upside potential than Stryker, analysts believe Pro-Dex is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    SYK
    Stryker
    13 9 0
  • Is PDEX or SYK More Risky?

    Pro-Dex has a beta of 0.169, which suggesting that the stock is 83.086% less volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

  • Which is a Better Dividend Stock PDEX or SYK?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Pro-Dex pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PDEX or SYK?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Stryker quarterly revenues of $5.9B. Pro-Dex's net income of $3.3M is lower than Stryker's net income of $654M. Notably, Pro-Dex's price-to-earnings ratio is 14.54x while Stryker's PE ratio is 50.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.13x versus 6.27x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.13x 14.54x $17.4M $3.3M
    SYK
    Stryker
    6.27x 50.96x $5.9B $654M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
37
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
RGC alert for Jun 17

Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.

Buy
75
ARQQ alert for Jun 17

Arqit Quantum [ARQQ] is up 6.36% over the past day.

Buy
59
SYM alert for Jun 17

Symbotic [SYM] is down 3.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock